Evidence map›Paper›PMID 40679713›Full record

ArticleBreast cancer research and treatment2025

Clinical subtypes and prognosis of invasive breast cancer with Paget's disease: a SEER study.

Soo Youn Bae, Chai Won Kim, Jehyun Chin, Jin Ah Lee, Dooreh Kim, Young Joo Lee, Chang Ik Yoon, Woo-Chan Park

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Soo Youn BaeDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea. baessu@gmail.com.ORCID http://orcid.org/0000-0003-0551-7618
Chai Won KimDepartment of Surgery, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Jehyun ChinDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Jin Ah LeeDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Dooreh KimDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Young Joo LeeDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Chang Ik YoonDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Woo-Chan ParkDepartment of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePaget's disease of the breast is rare but commonly associated with underlying carcinoma. Despite frequent HER2 overexpression, its clinical relevance in Paget's disease remains unclear. We evaluated the prognostic impact of ER and HER2 expression in invasive ductal carcinoma (IDC) with Paget's disease and assessed whether clinical subtypes affect survival outcomes.

methodsUsing SEER 17 data, we identified patients with IDC and HER2 status available, diagnosed from 2010 onward. Two groups were analyzed: IDC with Paget's disease (ICD-O-3 code 8541/3, n = 1,000) and IDC alone (ICD-O-3 code 8500/3, n = 487,162).

resultsCompared to IDC alone, patients with Paget's disease had lower ER (60.5% vs. 82.0%) and PR (45.5% vs. 71.7%) expression, and higher HER2 overexpression (52.5% vs. 15.4%) (all P < 0.001). The ER + HER2 - subtype was less common in the Paget's group (34.9% vs. 71.6%), while ER - HER2 + was more frequent (29.2% vs. 4.8%) (P < 0.001). Among ER + HER2 - and ER + HER2 + subtypes, those with Paget's disease had worse breast cancer-specific survival (BCSS) than those with IDC alone (HR 1.519, 95% CI 1.074-2.149; HR 1.030, 95% CI 1.027-1.033, respectively). No BCSS differences were observed in ER - HER2 - and ER - HER2 + subtypes.

conclusionER + HER2 - subtype in IDC with Paget's disease is linked to worse BCSS, differing from IDC alone. These findings suggest distinct tumor biology in IDC with Paget's disease, highlighting the need for subtype-specific management strategies.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastPaget's Disease, MammaryAdultAgedAged, 80 and overBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneSEER ProgramBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancer-specific survival (BCSS)Estrogen receptor (ER)HER2 overexpressionInvasive ductal carcinoma (IDC)Paget’s disease of the breast

Identifiers

PMID40679713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.